A5091376212- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Viral-associated cancers and disorders
- Neutropenia and Cancer Infections
- Renal Transplantation Outcomes and Treatments
- Immune Cell Function and Interaction
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Anesthesia and Pain Management
- Chemokine receptors and signaling
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Nausea and vomiting management
- CNS Lymphoma Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Transplantation: Methods and Outcomes
- Anesthesia and Sedative Agents
- T-cell and Retrovirus Studies
Kuopio University Hospital
2016-2025
University of Eastern Finland
2018
Moisio Hospital
2015-2016
Orion Corporation (Finland)
2003
Oulu University Hospital
2000
University of Oulu
2000
The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia (AML) in patients not benefiting from intensive chemotherapy. Nevertheless, failure remains a challenge, and predictive markers are needed, particularly for relapsed or refractory AML. Ex vivo drug sensitivity testing may correlate with outcomes, but its prospective value unexplored. Here we report results first stage phase II VenEx trial evaluating utility predictiveness using different cell culture...
Abstract Hodgkin’s lymphoma (HL) is a lymphoid malignancy with an emphasized incidence in developed countries. This study aimed to assess the changes epidemiology of HL Finland at population level by utilizing data from six nationwide healthcare registries. A total 2912 patients HL, diagnosed and treated between 2000 2019 were matched controls divided into younger (<50 years) older cohorts (≥50 for analysis. slightly increasing trend per age group was observed. For patients, mean...
Plerixafor (PLER), a reversible antagonist of the CXC chemokine receptor type 4, has been in clinical use for mobilization blood grafts autologous hematopoietic cell transplantation (AHCT) about 15 years. Initially PLER was investigated placebo-controlled trials with granulocyte colony-stimulating factor (G-CSF) filgrastim. It also used combination chemotherapy plus G-CSF patients who had failed previous attempt or appeared to mobilize poorly current (preemptive use). This review summarizes...
Early lymphocyte recovery as manifested by an absolute count at d+15 (ALC-15) ≥ 0.5 × 109/L after autologous hematopoietic stem cell transplantation (AHCT) has been associated with a better outcome. This prospective multicenter study aimed to clarify factors ALC-15 AHCT among 178 patients non-Hodgkin lymphoma. The mobilization capacity, peak blood CD34+ numbers > 45 106/L correlated higher levels (p = 0.020). In addition, the amount of CD3+CD4+ T cells 31.8 106/kg in infused graft...
Background: Ropivacaine is the first S‐enantiomer aminoamide local anaesthetic in clinical use, and has been found to be less toxic than bupivacaine. Caudal ropivacine shown cause motor blockade longer duration of analgesia postoperative period bupivacaine children. Plasma levels ropivacaine have not previously compared This study was undertaken compare total venous plasma concentrations similar doses following caudal administration. Methods: Blood samples were obtained determine used 30...
BACKGROUND Autologous stem cell transplantation is commonly used to treat non‐Hodgkin's lymphomas (NHLs). Cellular composition of the blood grafts apparently has a role in posttransplant hematologic and immune recovery. Plerixafor increases mobilization CD34+ cells higher amounts various lymphocyte subsets have been reported grafts. Limited prospective data are available regard graft cellular composition, recovery, patient outcomes NHL patients who receive plerixafor added chemomobilization....
Autologous stem cell transplantation (auto-SCT) is an established treatment option in patients with non-Hodgkin lymphoma (NHL). In this prospective multicenter study, the effect of infused blood graft cellular composition on post-transplant outcome was analyzed 129 NHL patients. Higher CD34+ content (>2.5 × 106/kg) correlated better progression-free survival (PFS) (p=.009) and overall (OS) (p=.004). CD34+CD133+CD38– counts (>0.08 were also linked PFS (p=.03) OS (p=.004), these benefits...
Abstract Autologous stem cell transplantation (ASCT) combined with novel agents is the standard treatment for transplant-eligible, newly diagnosed myeloma (NDMM) patients. Lenalidomide approved maintenance after ASCT until progression, although optimal duration of unknown. In this trial, 80 patients NDMM received three cycles lenalidomide, bortezomib, and dexamethasone followed by lenalidomide progression or toxicity. The primary endpoint was proportion flow-negative Molecular response...
Abstract Background Autologous stem cell transplantation (auto‐SCT) is a widely used treatment option in multiple myeloma (MM) patients. The optimal graft cellular composition not known. Study design and methods Autograft was analyzed after freezing by flow cytometry 127 MM patients participating prospective multicenter study. impact of on hematologic recovery outcome auto‐SCT evaluated. Results A higher CD34 + content predicted faster platelet both the short long term. In with standard‐risk...
BACKGROUND Autologous stem cell transplantation is an established treatment option for patients with multiple myeloma (MM) or non‐Hodgkinʼs lymphoma (NHL). STUDY DESIGN AND METHODS In this prospective multicenter study, 147 MM were compared 136 NHL regarding the mobilization and apheresis of blood CD34+ cells, cellular composition infused grafts, posttransplant recovery, outcome. RESULTS Multiple mobilized cells more effectively (6.3 × 10 6 /kg vs. 3.9 /kg, p = 0.001). The proportion poor...
Abstract Background Diffuse large B‐cell lymphoma (DLBCL) is a common indication for autologous stem cell transplantation (auto‐SCT). Study Design and Methods This prospective noninterventional study aimed to evaluate the impact of mobilization characteristics graft cellular content on hematologic recovery outcome after auto‐SCT among 68 patients with DLBCL. Results Better capacity as manifested by blood CD34 + count >32 × 10 6 /L yield first apheresis >2.75 /kg correlated faster...
Primary central nervous system lymphoma is a rare but aggressive brain malignancy. It associated with poor prognosis even the current standard of care. The aim this study was to evaluate effect and tolerability blood–brain barrier disruption treatment combined high-dose autologous stem cell transplantation as consolidation on primary patients. We performed prospective phase II for 25 patients previously untreated lymphoma. initiated 3–4 weeks after MATRix regimen using optimized therapy...
BACKGROUND Lenalidomide is an immunomodulatory drug that also currently used in transplant‐eligible patients with multiple myeloma. Previous studies have suggested a negative impact of lenalidomide on the mobilization CD34 + cells. No data are available regarding more detailed composition blood grafts after lenalidomide. STUDY DESIGN AND METHODS In multicenter, prospective study, we analyzed cells, graft cellular composition, and post‐transplant hematologic recovery 26 myeloma...
The composition of autologous blood grafts after cryopreservation, post-transplant hematological recovery up to 1 year and immune 6 months as well outcome was analyzed in 87 patients with multiple myeloma (MM). receiving added plerixafor due poor mobilization (11%) were compared those mobilized G-CSF or cyclophosphamide (CY) plus G-CSF. use found significantly affect the graft there a higher proportion more primitive CD34+ cells, number T B lymphocytes NK cells who received also plerixafor....
Abstract Background Prospective data on the impact of CD34 + cell loss during cryopreservation and amount cryopreserved cells infused after high‐dose therapy hematologic recovery post‐transplant outcome in multiple myeloma (MM) are scarce. Patients methods This post‐hoc study aimed to investigate factors associating with effects infusion a very low number (<1.0 × 10 6 /kg, group A), (1–1.9 B), optimal (≥2 C) thawed viable recovery, progression free survival, overall survival autologous...
BACKGROUND Data are limited on the long‐acting granulocyte‐colony stimulating factors (G‐CSFs) pegfilgrastim (PEG) and lipegfilgrastim (LIPEG) compared with filgrastim (FIL) regarding mobilization efficiency of CD34 + cells, graft cellular composition, engraftment. STUDY DESIGN AND METHODS In this prospective nonrandomized study, 36 patients non‐Hodgkin lymphoma received FIL, 67 PEG, 16 LIPEG as a cytokine after chemotherapy. We analyzed collection composition blood grafts, hematologic...
Abstract Background Scarce data exist on the impact of granulocyte‐colony stimulating factor (G‐CSF) type mobilizing capacity CD34 + cells, graft cellular composition, and outcome in myeloma (MM) patients. Patients Methods In this prospective multicenter study, 70 patients with MM received filgrastim (FIL) 20 pegfilgrastim (PEG) as a G‐CSF after low‐dose cyclophosphamide. Flow cytometry was used to analyze mobilization cells composition blood grafts, hematologic recovery, survival auto‐SCT...
The bone marrow microenvironment interacts with malignant cells and regulates cancer survival immune evasion in multiple myeloma (MM). We investigated the profiles of longitudinal samples from patients newly diagnosed MM (n = 18) using cytometry by time-of-flight. results before during treatment were compared between good (GR, n 11) bad (BR, 7) responses to lenalidomide/bortezomib/dexamethasone-based treatment. Before treatment, GR group had a lower tumor cell burden higher number T...
Autologous stem cell transplantation (ASCT) is a standard treatment in transplant-eligible mantle lymphoma (MCL) patients after first-line chemoimmunotherapy.This prospective multicenter study evaluated the impact of CD34+ mobilization and graft cellular composition analyzed by flow cytometry on hematologic recovery outcome 42 MCL patients.During mobilization, higher blood count (>30 × 106/L) was associated with improved overall survival (median not reached [NR] vs. 57 months, p = 0.04). The...